About TRYNGOLZA

Patient satisfaction with TRYNGOLZA as reported in the Balance study

Patient interviews demonstrate a high level of satisfaction with TRYNGOLZA treatment2

83% (15/18)

of patients reported meaningful improvements in ≥1 of the following:

Decreased frequency of acute pancreatitis (AP) events

Fewer, less frequent, and less severe AP events were mentioned most often as patients' most important improvements

Fewer FCS symptoms, such as abdominal pain, pancreatitis, and physical fatigue

Improvements in FCS impacts, such as impacts of FCS, such as everyday activities, mood and emotions, and relationships

83% (15/18)

of patients reported being “satisfied” or “very satisfied” with TRYNGOLZA2

  • Very satisfied: 8/18
  • Satisfied: 7/18
  • Dissatisfied: 2/18
  • Very dissatisfied: 1/18

Real patient quotes2

“

Very satisfied, just seeing my results.”

“

With this study, given that I haven’t experienced [pancreatitis] episodes…I feel relieved even knowing that I have to continuously go on business trips…”

Study design2: Qualitative interviews were completed with 18 patients from the Balance trial and its associated open-label extension (OLE). The OLE study includes a 157-week treatment period with TRYNGOLZA, and all patients were eligible for the interview substudy after completing Week 13 of the OLE study. Objectives included capturing patients' experiences prior to starting the Balance study, the effect of study treatment on the symptoms and impacts related to FCS during Balance or the OLE study, and to characterize the meaningfulness of any changes experienced during treatment.

In addition to the Balance study, TRYNGOLZA has been used in clinical practice since FDA approval in 2024.1